Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for InVivo Therapeutics Holdings Corp. (NVIV : NSDQ)
 
 • Company Description   
InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts.

Number of Employees: 7

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.54 Daily Weekly Monthly
20 Day Moving Average: 25,753 shares
Shares Outstanding: 1.39 (millions)
Market Capitalization: $6.32 (millions)
Beta: 1.26
52 Week High: $23.19
52 Week Low: $3.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -20.59% -10.58%
12 Week -33.36% -26.74%
Year To Date -60.18% -51.56%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
ONE KENDALL SQUARE SUITE B14402
-
CAMBRIDGE,MA 02139
USA
ph: 617-863-5500
fax: -
info@invivotherapeutics.com http://www.invivotherapeutics.com
 
 • General Corporate Information   
Officers
Richard Toselli - Chief Executive Officer;President
C. Ann Merrifield - Chair of the Board
Richard Christopher - Chief Financial Officer
Daniel R. Marshak - Director
Christina Morrison - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 46186M605
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
Share - Related Items
Shares Outstanding: 1.39
Most Recent Split Date: 4.00 (0.04:1)
Beta: 1.26
Market Capitalization: $6.32 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.41
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 3.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -53.04
12/31/21 - -45.03
09/30/21 - -41.25
ROA
03/31/22 - -46.05
12/31/21 - -40.04
09/30/21 - -37.08
Current Ratio
03/31/22 - 7.70
12/31/21 - 7.33
09/30/21 - 10.64
Quick Ratio
03/31/22 - 7.70
12/31/21 - 7.33
09/30/21 - 10.64
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 11.15
12/31/21 - 13.22
09/30/21 - 15.28
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©